Technical Analysis for ATXI - Avenue Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| See historical ATXI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 22 | Narrow Range Bar | Range Contraction | 0.00% |
| Mar 22 | NR7 | Range Contraction | 0.00% |
| Mar 22 | Inside Day | Range Contraction | 0.00% |
| Mar 21 | 20 DMA Resistance | Bearish | 0.94% |
| Mar 21 | MACD Bearish Signal Line Cross | Bearish | 0.94% |
| Mar 21 | 180 Bearish Setup | Bearish Swing Setup | 0.94% |
| Mar 21 | Bollinger Band Squeeze | Range Contraction | 0.94% |
| Mar 21 | Outside Day | Range Expansion | 0.94% |
| Mar 21 | Down 3 Days in a Row | Weakness | 0.94% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-07
- Sector: Healthcare
- Industry: Biopharmaceuticals
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Pharmaceutical Drugs Chemical Compounds Pharmacokinetics Analgesics Neurochemistry Hepatotoxins Amines Opioid Paracetamol
Pharmaceutical Drugs Chemical Compounds Pharmacokinetics Analgesics Neurochemistry Hepatotoxins Amines Opioid Paracetamol
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ATXI news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.82 |
| 52 Week Low | 2.08 |
| Average Volume | 46,642 |
| 200-Day Moving Average | 4.4449 |
| 50-Day Moving Average | 5.7528 |
| 20-Day Moving Average | 5.4885 |
| 10-Day Moving Average | 5.551 |
| Average True Range | 0.3194 |
| ADX | 13.25 |
| +DI | 10.9938 |
| -DI | 13.2507 |
| Chandelier Exit (Long, 3 ATRs ) | 4.9318 |
| Chandelier Exit (Short, 3 ATRs ) | 6.0782 |
| Upper Bollinger Band | 5.8154 |
| Lower Bollinger Band | 5.1616 |
| Percent B (%b) | 0.33 |
| BandWidth | 11.91218 |
| MACD Line | -0.0527 |
| MACD Signal Line | -0.0446 |
| MACD Histogram | -0.0081 |
| Fundamentals | Value |
|---|---|
| Market Cap | 54.02 Million |
| Num Shares | 10 Million |
| EPS | -0.44 |
| Price-to-Earnings (P/E) Ratio | -12.23 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 1.57 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.60 | ||||
| Resistance 3 (R3) | 5.59 | 5.50 | 5.57 | ||
| Resistance 2 (R2) | 5.50 | 5.44 | 5.51 | 5.55 | |
| Resistance 1 (R1) | 5.44 | 5.41 | 5.40 | 5.45 | 5.54 |
| Pivot Point | 5.35 | 5.35 | 5.33 | 5.36 | 5.35 |
| Support 1 (S1) | 5.29 | 5.29 | 5.25 | 5.31 | 5.22 |
| Support 2 (S2) | 5.20 | 5.26 | 5.21 | 5.21 | |
| Support 3 (S3) | 5.14 | 5.20 | 5.19 | ||
| Support 4 (S4) | 5.16 |
